Rheumatoid lung disease is a group of lung problems caused by rheumatoid arthritis (RA), the same immune system malfunction that attacks your joints. The lungs are one of the most common organs affected outside the joints, and the disease can take several forms: scarring of lung tissue, inflammation of the lining around the lungs, fluid buildup, airway obstruction, and lung nodules. Around 25% of people with RA show signs of lung involvement on imaging, even when they have no breathing symptoms.
How RA Damages the Lungs
The same overactive immune response that causes joint inflammation can target lung tissue. In RA, the immune system produces antibodies against proteins that have undergone a chemical change called citrullination. These antibodies, which can appear in the blood years before joint symptoms start, accumulate in the lungs and trigger inflammation that damages the delicate air sacs and surrounding tissue.
People with RA-related lung disease have significantly higher levels of these antibodies compared to RA patients without lung involvement, and the enzymes that drive citrullination are also elevated in their lung tissue. Over time, this ongoing immune attack can cause scarring (fibrosis) that stiffens the lungs and makes it harder to exchange oxygen. Cigarette smoke is a known trigger for this process, as it accelerates the chemical changes in lung proteins that provoke the immune response.
Types of Lung Involvement
Interstitial Lung Disease
Interstitial lung disease (ILD) is the most common and most studied form. It involves scarring and inflammation of the tissue between the air sacs, which progressively reduces lung function. The two most frequent patterns are usual interstitial pneumonia (UIP), which shows a honeycomb-like scarring pattern on CT scans concentrated in the lower lungs, and nonspecific interstitial pneumonia (NSIP), which appears as hazy, ground-glass patches spread more evenly across both lungs. UIP tends to be more progressive and harder to treat. Less common patterns include organizing pneumonia and acute interstitial pneumonia.
Pleural Disease
The pleura, a thin membrane surrounding the lungs, is frequently affected. Inflammation of this lining (pleuritis) and fluid accumulation (pleural effusion) are the most common pleural problems. Notably, pleural disease can appear before or at the same time as joint symptoms, sometimes serving as the first sign of RA. Large effusions can cause cough, shortness of breath, chest pain, and fever.
Lung Nodules
Rheumatoid nodules are lumps of inflamed tissue that form in the lung, usually near the surface. They can be single or multiple, and occasionally develop cavities. These nodules are found in roughly 4% of RA patients on high-resolution CT scans, and they’re more likely in people exposed to industrial dust like silica, asbestos, or coal. The good news is that lung nodules generally carry a good prognosis and may shrink or disappear on their own over time.
Airway Disease
RA can also affect the airways themselves, causing conditions like bronchiectasis (permanent widening and damage of the breathing tubes), follicular bronchiolitis, and constrictive bronchiolitis, where the smallest airways become narrowed and obstructed. These airway problems can cause chronic cough and progressive shortness of breath.
Symptoms and How They Develop
The hallmark symptoms are a persistent dry cough and gradually worsening shortness of breath, particularly with physical activity. These tend to develop slowly, which is why many people attribute them to aging or being out of shape. A doctor listening with a stethoscope may hear distinctive “Velcro-like” crackling sounds in the lower lungs, a telltale sign of interstitial scarring.
In many cases, lung changes are already underway before symptoms appear. Prospective studies using high-resolution CT scans have found subclinical ILD in about 25% of RA patients, meaning the scarring is visible on imaging but hasn’t yet caused noticeable breathing problems. This is why screening matters, especially for people at higher risk.
Who Is Most at Risk
Not everyone with RA develops lung disease, but certain factors raise the odds substantially. A large meta-analysis identified the following key risk factors:
- Male sex: Men with RA are roughly twice as likely to develop ILD as women, despite RA itself being more common in women.
- Age over 60: Older age increases risk by about 42%.
- Later onset of RA: Being diagnosed with RA at an older age is an independent risk factor.
- Smoking: Smokers face a 37% higher risk, and smoking also accelerates the immune processes that drive lung damage.
- Positive rheumatoid factor: Testing positive for this antibody is associated with higher rates of lung involvement.
- Existing lung problems: Having other pulmonary conditions raises risk further.
How It’s Diagnosed
High-resolution CT (HRCT) scanning is the primary imaging tool. It can reveal the specific pattern of lung damage, which helps guide treatment decisions. UIP shows up as a web of scarring with honeycombing concentrated in the lower, outer portions of the lungs. NSIP appears as more diffuse haziness with fine lines of scarring, spread relatively symmetrically.
Pulmonary function tests (PFTs) measure how well your lungs move air and transfer oxygen into the blood. A key measurement is the diffusing capacity, which reflects how efficiently oxygen crosses from the air sacs into the bloodstream. In rheumatoid lung disease, this number drops as scarring thickens the barrier between air and blood.
For RA patients with a persistent cough or shortness of breath lasting more than three months, current screening recommendations call for a chest X-ray and pulmonary function tests first, followed by HRCT if those results are abnormal. Even asymptomatic patients with multiple risk factors may benefit from direct HRCT screening. Annual check-ins that include lung auscultation and questions about breathing symptoms are recommended for all RA patients.
Treatment Options
The 2023 guidelines from the American College of Rheumatology and the American College of Chest Physicians outline a treatment approach that focuses on calming the immune system to slow or stop lung damage. First-line options include three immunosuppressive medications: mycophenolate, azathioprine, and rituximab (a biologic that targets specific immune cells). Short-term corticosteroids are also conditionally recommended as initial treatment to reduce active inflammation.
If the disease progresses despite first-line treatment, rituximab and mycophenolate are both recommended as next steps for patients who didn’t start on them initially. An antifibrotic medication called nintedanib, which slows the scarring process itself rather than targeting the immune system, is conditionally recommended for progressive disease after first-line therapy, though it hasn’t reached consensus as an initial treatment.
One important consideration is that some medications commonly used to treat RA joint symptoms can themselves cause lung problems. This makes coordination between rheumatology and pulmonary specialists essential.
Prognosis and Long-Term Outlook
The outlook for rheumatoid lung disease varies widely depending on the type and severity. Pleural disease and lung nodules tend to have a relatively favorable course. ILD, however, is more serious and is the form most closely tied to reduced life expectancy.
A systematic review pooling data from multiple studies found that median survival after an RA-ILD diagnosis ranges from 2 to 14 years, reflecting the wide spectrum of disease severity. Cumulative mortality rates tell a clearer story: about 9% within the first year, 21% by three years, 30% by five years, and 49% by ten years. The UIP pattern tends to carry a worse prognosis than NSIP.
Once ILD is confirmed, pulmonary function tests are typically repeated every 3 to 12 months during the first year to track whether the disease is stable or progressing. After that, the testing schedule is adjusted based on how things are going. For high-risk patients being monitored but not yet diagnosed with ILD, annual pulmonary function tests and CT scans every two years are recommended. Early detection of progression allows treatment to be adjusted before significant lung function is lost.